Michel Reijnen (Arnhem, The Netherlands) presents the results of a study that sought to assess the potential cost-effectiveness of a urea-based drug-coated balloon (DCB; IN.PACT Admiral, Medtronic) as standard of care treatment for those with chronic limb threatening ischaemia (CLTI) within the Dutch and German healthcare settings.
Reijnen looks at the rising trend in national healthcare spending which he notes indicates that “cost-effectiveness is becoming more and more important” and goes on to outline the study design and some of the key results of the quality-adjusted life year (QALY) analysis. In fact, although the procedure costs were slightly higher in the DCB group, the target lesion revascularisation and amputation costs were found to be higher in the status quo group. This ultimately meant a cost saving for DCB use across both healthcare communities.
This video is sponsored by Medtronic.
